Lessons in Rapid Innovation From the COVID-19 Pandemic

The coronavirus pandemic is one of the most difficult collective challenges facing humanity since the last world war. In the midst of the turmoil, national health authorities, pharmaceutical companies, universities, and research institutes are racing to find therapies to save lives and contain the grave social and economic consequences of the pandemic. As organizations and experts scramble to innovate therapies, they are also redefining innovation. The conventional approach to innovation in the pharmaceutical industry is to conduct a lengthy process that starts with the discovery and generation of potential drug compounds and moves through a meticulous refinement and selection phase toward gradual development, clinical testing, and market approval. Although this model will continue to be the most effective in future drug development, it is now being complemented with an ultrafast approach to innovation centered on the repurposing of readily available ideas, knowledge, and technologies.